Clinical trial · Observational
Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients
Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutations in Patients With Advanced or Metastatic NSCLC at Front-line and Progression
NCT03721289CI-TRIAL-00039050PANORAMRETROcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluate molecular testing and treatment patterns for EGFR mutation in two different cohorts of stage IV NSCLC, at diagnosis (treatment naïve) and at the moment of progression to EGFR-TKIs. This study is non-indication seeking (NIS), descriptive in nature and does not attempt to test any specific a priori hypotheses.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Cohort 1
- description
- All registered cases of stage IV NSCLC patients, treatment naïve, diagnosed in the participant institution during one year (from Jan 1st 2017 to Dec 31st 2017).
- label
- Cohort 2
- description
- All EGFR positive patients progressed to an EFGR-TKI in the same period of time (from Jan 1st 2017 to Dec 31st 2017)
Primary outcomes (1)
- measure
- Evaluation of the EGFR mutation
- timeFrame
- Clinical charts from January 2013-december 2017
- description
- Test used to determine EGFRm, registered in clinical charts
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria Cohort 1 * Adult male or female patients ≥ 18 years of age * Newly diagnosed patients with stage IV NSCLC who are treatment naïve, from 1st Jan 2017 to Dec 31st 2017 * For patients still avile, provision of written informed consent as per local regulations Cohort 2 * Adult male or female patients ≥ 18 years of age * Patinets Stage IV NSCLC progressed after a first line TKI from 1st Jan 2017 to Dec 31st 2017. * For patients still avile, provision of written informed consent as per local regulations In the case one patient meets eligibility criteria for both cohorts, this patient will be included only in the EFGR-TKI progressed cohort. Exclusion Criteria • There are not exclusion criteria to this study. For an overview on the guidelines to determine disease progression, refer to Appendix A (Section 11).
References
Publications (0)
Data not yet available
No reference posted for this study.